GRNA GREENLIGHT BIOSCIENCES HOLDINGS PBC

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

  • GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm



  • Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide



  • The Australian government has been searching for a more environmentally-friendly solution to fall armyworm and is supporting the partnership with a AUD$400,000 grant

BOSTON and BRISBANE, Australia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Researchers from Boston’s and the  (QUT) in Brisbane, Australia, have announced an agreement to develop a solution to fall armyworm, which causes more than US$2 billion in annual global crop loss.

The partnership includes an Australian government grant to QUT of more than AUD$400,000 from the Australian Research Council. It brings together the teams of two preeminent researchers, Dr. Julia Bally and Professor Peter Waterhouse from the QUT , and GreenLight’s Plant Health research and development team.

The partnership aims to develop a solution for fall armyworm, a pest of national priority in Australia. It is also a point of emphasis that the project delivers environmentally-friendly crop protection tools against fall armyworm.

GreenLight’s is working on producing RNA-based solutions for and that cause massive and annually. In lab tests and field trials, GreenLight’s RNA-based solutions leave low or no residues.

Dr. Bally said previous collaboration on fall armyworm with GreenLight had been important to securing the grant from the Australian Research Council this year.

"We are excited to work with GreenLight Biosciences on this solution to armyworm," she said. "We believe furthering our partnership will generate comprehensive new technologies to fight against one of the most damaging global crop pests and greatly improve Australian agritech capacity and strengthen international collaborations.”

GreenLight’s Vice President of Plant Health R&D Ron Flannagan said: “Fall armyworm has recently invaded Australia and devastates many crops, including sorghum and cotton. Our RNA platform allows us to develop solutions faster and more efficiently than was previously possible. So we are delighted to partner with QUT to accelerate our work targeting the fall armyworm with a sustainable solution.”

The project will begin with lab studies and advance to greenhouse and field trials.

“We believe this research will provide significant benefits, such as added security for Australia’s most important agricultural crops and regions and global food production," Dr. Bally said.

About GreenLight Biosciences

GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In , this includes RNA to and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit /

Press contact:

David Pesci

Head of Media Relations

For press, email:

For investors, email:

A photo accompanying this announcement is available at



EN
05/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GREENLIGHT BIOSCIENCES HOLDINGS PBC

 PRESS RELEASE

GreenLight Announces Completion of Merger with Fall Line Endurance Fun...

GreenLight Announces Completion of Merger with Fall Line Endurance Fund LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and G...

 PRESS RELEASE

GreenLight Biosciences Announces Expiration of Tender Offer Period for...

GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023 LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc (“Parent”). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading ...

 PRESS RELEASE

GreenLight Biosciences Enters into Definitive Merger Agreement with Co...

GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million. Pursuant to the terms of the Merger Agreement, and subject to ...

 PRESS RELEASE

GreenLight Biosciences Announces First Quarter 2023 Financial Results ...

GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023. “GreenLight is sharply focused on its mission, leveraging scientific expertise, global partnerships, and the power of our platform to progress innovative RNA-based products for pl...

 PRESS RELEASE

GreenLight Biosciences Releases Inaugural Sustainability Report

GreenLight Biosciences Releases Inaugural Sustainability Report BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural . The report contains the company's sustainability roadmap and includes sustainability updates on its business areas—from developing new tools for farmers that are designed to be targeted, effective, and environmentally responsible to vaccine candidates and p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch